Hepatitis B related fibrosis
Conditions
Interventions
Intervention group:Taohong Siwu Decoction plus conventional treatment
Control group:Conventional treatment
Sponsors
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 65 years, male or female. (2) Meet the diagnostic criteria for liver fibrosis. (3) Meet the diagnostic criteria of chronic hepatitis B and ALT < 3 x ULN. (4) Comply with the diagnosis of blood stasis blocking collaterals syndrome in Chinese medicine. (5) Voluntarily participate in the research, sign the informed consent form, and guarantee to receive follow-up.
Exclusion criteria
Exclusion criteria: (1) Have taken iron-containing drugs in the previous three months (2) Liver fibrosis caused by other causes. (3) Patients with other serious fatal liver diseases or complications, such as liver failure, septic shock, hepatic encephalopathy, hepatorenal syndrome, upper gastrointestinal bleeding. (4) Severe diseases of the heart, kidney, brain, breathing, blood and other systems or other organs. (5) Pregnant or lactating women or patients who have a pregnancy plan, patients with previous mental illness, epilepsy and other serious neurological or psychological diseases and alcoholic or drug addicts. (6) Patients who have been participating in other drug clinical trials for nearly 3 months or received other Chinese medicine treatment. (7) Patients with allergies or known allergies to the ingredients of this medicine. (8) Patients have poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver stiffness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Laminin;Procollagen type III;Collage Type IV;ALT;AST;Hyaluronic acid; | — |
Countries
China
Contacts
Public ContactSuping Ma
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Outcome results
None listed